

# Haydn T Kissick

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1256562/haydn-t-kissick-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

73  
papers

3,244  
citations

23  
h-index

56  
g-index

77  
ext. papers

4,623  
ext. citations

10  
avg, IF

5.13  
L-index

#	Paper	IF	Citations
73	Phase 2 study of neoadjuvant cabozantinib in patients with locally advanced non-metastatic clear cell renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 340-340	2.2	1
72	Case Report: Exceptional Response to Nivolumab Plus Ipilimumab in a Young Woman With TFE3-SFPQ Fusion Translocation-Associated Renal Cell Carcinoma.. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 793808	5.3	0
71	Defining HPV-specific B cell responses in patients with head and neck cancer. <i>Nature</i> , <b>2021</b> , 597, 274-278	50.4	48
70	CMV Status Drives Distinct Trajectories of CD4+ T Cell Differentiation. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 620386	8.4	0
69	Transcriptional firing represses bactericidal activity in cystic fibrosis airway neutrophils. <i>Cell Reports Medicine</i> , <b>2021</b> , 2, 100239	18	4
68	Baseline modified Glasgow prognostic score (mGPS) in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e16546-e16546	2.2	
67	A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 4836-4847	12.9	6
66	Body Composition Variables as Radiographic Biomarkers of Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 707050	5.3	3
65	Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. <i>Oncologist</i> , <b>2021</b> , 26, e1742-e1750	5.7	5
64	Organized immune cell interactions within tumors sustain a productive T-cell response. <i>International Immunology</i> , <b>2021</b> , 33, 27-37	4.9	3
63	Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors. <i>Oncologist</i> , <b>2021</b> , 26, 397-405	5.7	4
62	Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors. <i>Oncologist</i> , <b>2021</b> , 26, 1017-1025	5.7	1
61	Functional HPV-specific PD-1 stem-like CD8 T cells in head and neck cancer. <i>Nature</i> , <b>2021</b> , 597, 279-284	50.4	28
60	Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors. <i>Cancer Medicine</i> , <b>2020</b> , 9, 2752-2760	4.8	12
59	CD45RB Status of CD8 T Cell Memory Defines T Cell Receptor Affinity and Persistence. <i>Cell Reports</i> , <b>2020</b> , 30, 1282-1291.e5	10.6	5
58	Association of baseline modified Glasgow Prognostic Score (mGPS) with survival outcomes in patients with metastatic urothelial cell carcinoma (mUCC) treated with immune checkpoint inhibitors (CPI).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 563-563	2.2	1
57	Association of modified Glasgow Prognostic Score (mGPS) with survival outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (CPI).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 738-738	2.2	1

56	Considerations for cancer immunotherapy biomarker research during COVID-19. <i>Endocrine-Related Cancer</i> , <b>2020</b> , 27, C1-C8	5.7	
55	Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy. <i>Oncologist</i> , <b>2020</b> , 25, e528-e535	5.7	26
54	Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. <i>Oncologist</i> , <b>2020</b> , 25, e484-e491	5.7	17
53	T Cell Receptor Diversity and Lineage Relationship between Virus-Specific CD8 T Cell Subsets during Chronic Lymphocytic Choriomeningitis Virus Infection. <i>Journal of Virology</i> , <b>2020</b> , 94,	6.6	7
52	Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials. <i>Cancer</i> , <b>2020</b> , 126, 575-582	6.4	24
51	The immunosuppressive phenotype of tumor-infiltrating neutrophils is associated with obesity in kidney cancer patients. <i>OncImmunity</i> , <b>2020</b> , 9, 1747731	7.2	3
50	Neoadjuvant Cabozantinib in an Unresectable Locally Advanced Renal Cell Carcinoma Patient Leads to Downsizing of Tumor Enabling Surgical Resection: A Case Report. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 622134	5.3	1
49	Phosphoinositide 3-Kinase Signaling Can Modulate MHC Class I and II Expression. <i>Molecular Cancer Research</i> , <b>2019</b> , 17, 2395-2409	6.6	19
48	Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials. <i>Investigational New Drugs</i> , <b>2019</b> , 37, 1198-1206	4.3	8
47	Novel risk stratification criteria of metastatic renal cell carcinoma (mRCC) patients (pts) treated with immune checkpoint inhibitors (ICI).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e16068-e16068	2.2	1
46	Association between immune-related adverse events (irAEs) and clinical outcomes (CO) in advanced urothelial cancer patients (pts) treated with immunotherapy (IO).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 472-472	2.2	1
45	Sites of metastases (mets) and their association with clinical outcomes (CO) in urothelial cancer patients (pts) treated with immunotherapy (IO).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 473-473	2.2	2
44	Inflammatory markers at baseline (C1) and cycle 3 (C3) and their association with clinical outcomes in urothelial cancer patients (pts) treated with immunotherapy (IO).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 390-390	2.2	
43	Immunological Complexity of the Prostate Cancer Microenvironment Influences the Response to Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , <b>2019</b> , 1210, 121-147	3.6	7
42	Reply to Tumor-associated macrophages: "Good cop-bad cop". <i>Cancer</i> , <b>2019</b> , 125, 1942-1943	6.4	
41	Proliferating Transitory T Cells with an Effector-like Transcriptional Signature Emerge from PD-1 Stem-like CD8 T Cells during Chronic Infection. <i>Immunity</i> , <b>2019</b> , 51, 1043-1058.e4	32.3	150
40	An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. <i>Nature</i> , <b>2019</b> , 576, 465-470	50.4	237
39	The requirement for immune infiltration and organization in the tumor microenvironment for successful immunotherapy in prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2019</b> , 37, 543-555	2.8	14

38	Expression of novel long noncoding RNAs defines virus-specific effector and memory CD8 T cells. <i>Nature Communications</i> , <b>2019</b> , 10, 196	17.4	28
37	The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy. <i>Cancer</i> , <b>2019</b> , 125, 127-134	6.4	71
36	CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions. <i>Annual Review of Medicine</i> , <b>2018</b> , 69, 301-318	17.4	265
35	Evaluation of programmed cell death protein 1 (PD-1) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma. <i>Oncotarget</i> , <b>2018</b> , 9, e1413519	7.2	15
34	Is It Possible to Develop Cancer Vaccines to Neoantigens, What Are the Major Challenges, and How Can These Be Overcome? Neoantigens as Vaccine Targets for Cancer. <i>Cold Spring Harbor Perspectives in Biology</i> , <b>2018</b> , 10,	10.2	5
33	Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab. <i>Clinical Genitourinary Cancer</i> , <b>2018</b> , 16, e563-e575	3.3	52
32	Extracellular vesicles from bone marrow-derived mesenchymal stromal cells support survival of human antibody secreting cells. <i>Journal of Extracellular Vesicles</i> , <b>2018</b> , 7, 1463778	16.4	19
31	Early change in blood-based biomarkers and association with clinical outcome (CO) in advanced stage cancer patients (pts) treated with immunotherapy (IO).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e15022-e15022	2.2	22
30	Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer. <i>Journal of Clinical Pharmacology</i> , <b>2018</b> , 58, 7-24	2.9	15
29	Gleason Score 7 Prostate Cancers Emerge through Branched Evolution of Clonal Gleason Pattern 3 and 4. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 3823-3833	12.9	30
28	Translation is actively regulated during the differentiation of CD8 effector T cells. <i>Nature Immunology</i> , <b>2017</b> , 18, 1046-1057	19.1	79
27	Origin and differentiation of human memory CD8 T cells after vaccination. <i>Nature</i> , <b>2017</b> , 552, 362-367	50.4	257
26	Effector CD8 T cells dedifferentiate into long-lived memory cells. <i>Nature</i> , <b>2017</b> , 552, 404-409	50.4	245
25	An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets. <i>Journal of Hematology and Oncology</i> , <b>2017</b> , 10, 107	22.4	26
24	Correlation between inflammatory markers in blood and expression of costimulatory molecules on tumor-infiltrating CD8+ lymphocytes in renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 508-508	2.3	23
23	Defining antigen-specific plasmablast and memory B cell subsets in human blood after viral infection or vaccination. <i>Nature Immunology</i> , <b>2016</b> , 17, 1226-34	19.1	202
22	Major histocompatibility complex I upregulation in clear cell renal cell carcinoma is associated with increased survival. <i>Asian Journal of Urology</i> , <b>2016</b> , 3, 75-81	2.7	4
21	Application of small RNA sequencing to identify microRNAs in acute kidney injury and fibrosis. <i>Toxicology and Applied Pharmacology</i> , <b>2016</b> , 312, 42-52	4.6	40

20	Understanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model. <i>Frontiers in Pharmacology</i> , <b>2016</b> , 7, 327	5.6	8
19	Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. <i>Nature</i> , <b>2016</b> , 537, 417-421	50.4	834
18	The transcription factor ERG increases expression of neurotransmitter receptors on prostate cancer cells. <i>BMC Cancer</i> , <b>2015</b> , 15, 604	4.8	4
17	Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway. <i>Forum on Immunopathological Diseases and Therapeutics</i> , <b>2015</b> , 6, 7-17		48
16	Bone metastasis in prostate cancer: Recurring mitochondrial DNA mutation reveals selective pressure exerted by the bone microenvironment. <i>Bone</i> , <b>2015</b> , 78, 81-6	4.7	35
15	The role of active vaccination in cancer immunotherapy: lessons from clinical trials. <i>Current Opinion in Immunology</i> , <b>2015</b> , 35, 15-22	7.8	27
14	High Expression of Major Histocompatibility Complex Class I in Clear Cell Renal Cell Carcinoma Is Associated with Improved Prognosis. <i>Urologia Internationalis</i> , <b>2015</b> , 95, 72-8	1.9	2
13	Successful combined intratumoral immunotherapy of established murine mesotheliomas requires B-cell involvement. <i>Journal of Interferon and Cytokine Research</i> , <b>2015</b> , 35, 100-7	3.5	5
12	Beyond immune checkpoint blockade: new approaches to targeting host-tumor interactions in prostate cancer: report from the 2014 Coffey-Holden prostate cancer academy meeting. <i>Prostate</i> , <b>2015</b> , 75, 337-47	4.2	9
11	Evaluation of major histocompatibility complex class I expression in clear cell renal cell carcinoma as a prognostic tool.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 469-469	2.2	
10	Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, 9887-92	11.5	166
9	Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response. <i>PLoS ONE</i> , <b>2014</b> , 9, e93231	3.7	11
8	The scavenger receptor MARCO modulates TLR-induced responses in dendritic cells. <i>PLoS ONE</i> , <b>2014</b> , 9, e104148	3.7	19
7	Topically applied Melaleuca alternifolia (tea tree) oil causes direct anti-cancer cytotoxicity in subcutaneous tumour bearing mice. <i>Journal of Dermatological Science</i> , <b>2012</b> , 67, 120-9	4.3	23
6	The Role of Regulatory T Cells in Mesothelioma. <i>Cancer Microenvironment</i> , <b>2012</b> , 5, 165-72	6.1	11
5	Tumour eradication and induction of memory against murine mesothelioma by combined immunotherapy. <i>Immunology and Cell Biology</i> , <b>2012</b> , 90, 822-6	5	5
4	Mechanisms of immune suppression exerted by regulatory T-cells in subcutaneous AE17 murine mesothelioma. <i>Journal of Interferon and Cytokine Research</i> , <b>2010</b> , 30, 829-34	3.5	4
3	Inhibition of established subcutaneous murine tumour growth with topical Melaleuca alternifolia (tea tree) oil. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2010</b> , 66, 1095-102	3.5	27

- 2 Combined intratumoral regulatory T-cell depletion and transforming growth factor- $\beta$  neutralization induces regression of established AE17 murine mesothelioma tumors. *Journal of Interferon and Cytokine Research*, **2009**, 29, 209-15 3.5 6
- 1 Alpha-Tocopheryl succinate: toxicity and lack of anti-tumour activity in immuno-competent mice. *Food and Chemical Toxicology*, **2008**, 46, 508-12 4.7 7